

Ticket #:	Request Date:	Request Time:
	•	•

PHYSICIAN CERTIFICATION PRIOR AUTHORIZATION FORM

A request for the patient identified below has been made for the dispensing of **Stivarga®** regorafenib. Based on recent clinical information, we require more information before this prescription can be paid by the patient's health benefit plan. Please fill out the following information and return to us as indicated below:

A. Mem	ber Information									
Patient Name:			Plan Name/Plan ID:							
Patient ID:		Patient Date of Birth:		Patient Contact Phone #:						
B Phys	sician Information									
Physician Name: Physician Address:										
Physician DEA #: Physician Phone #:				Physi	cian Fax #:					
Drug Name and Strength: Direction (SIG):		Direction (SIG):	QT		QTY and Days Supply:		NDC #:			
O Dhaw										
	macy Information by Name:	NABP #:	Pharma	cy Phone	e #:	Pharma	acy Fax #:			
D 011 1	all (. 1 . \						
D. Clini	cal Information (Please fil	ll out the following informa	tion: circle all that app	oly)						
 Does the patient have a diagnosis of metastatic colorectal cancer or locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST)? (Please fill out only the specific section related to diagnosis.) 							YES	NO		
<u>For</u>	Metastatic Colorectal Car	<u>ncer</u>								
2. Was the patient previously treated with a fluoropyrimidine-, oxaliplatin-, and irinotecan-bases chemotherapy regimen?								YES	NO	
3. Has the patient been previously treated with an anti-VEGF agent (bevacizumab, ziv-afibercept)?							YES	NO		
4.	4. If this patient has KRAS mutation, please document any previous anti-EGFR therapy:									
<u>For</u>	GIST									
5. Has this patient been previously treated with imatinib mesylate and sunitinib maleate?							YES	NO		
Authoria	zed Medical Signature:									
Telephone:					Date:					

When Completed Return To:

MC-Rx Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507 1-866-965-Drug (3784) / Fax # 866-999-7736

^{**}Please note that this form is to be completed by the prescribing physician. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). HIPAA does restrict the communication of PHI with providers for TPO related purposes.